Actelion Patent Agent

Actelion Enters Phase III With Novel Orexin Receptor Antagonist

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.

Actelion - <STRONG>New data on orexin receptor antagonist almorexant

Of almorexant is compatible with those required for an agent used in sleep disorders.   Actelion Almorexant is covered under a recently published patent application. Actelion is.

FinancialContent.com - Stock Quotes and Business News

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.

Actelion - <STRONG>Actelion announces Full Year 2006 financial results

Antibiotic agent and one oral anti-allergic agent.   In Research, Actelion resulted in the filing of 40 priority patent applications. At its current size and speed, Actelion’s.

Actelion Annual Report 2006 - Cornerstones - Drug Discovery

The discoveries of the 240 in-house scientists, who filed 40 patent Actelion expects an anti-bacterial agent from Drug Discovery to begin Phase I trials.

PipelineReview.com - Biotech News Center & Online Store - Actelion

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. 4 of 4 - Almorexant Phase III RESTORA.

Kiplinger.com

Of almorexant is compatible with those required for an agent used in sleep disorders. Actelion Almorexant is covered under a recently published patent application. Actelion is now.

Actelion Enters Phase III With Novel Orexin Receptor Antagonist

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.

Actelion - <STRONG>New data on orexin receptor antagonist

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered under a recently published patent application.

CIPO - Patent - 2402431

Property Office (CIPO) provides access to patent document 73) Owners: ( Country ) ACTELION PHARMACEUTICALS LTD. (Switzerland) 74) Agent: GOWLING LAFLEUR HENDERSON LLP (45) Issued:.

Actelion Annual Report 2006 - Cornerstones - Drug Discovery

The discoveries of the 240 in-house scientists, who filed 40 patent Actelion expects an anti-bacterial agent from Drug Discovery to begin Phase I trials in 2007:.

(WO/2002/024665) ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST

Applicants: ACTELION PHARMACEUTICALS LTD [CH/CH]; ACTELION LTD Agent: HOFMANN, Dieter ; StratAll Therwilerstrasse 87 CH Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD.

Actelion Announces Full Year 2006 Financial Results

Antibiotic agent and one oral anti-allergic agent. In Research, Actelion resulted in the filing of 40 priority patent applications. At its current size and speed, Actelion's.

(WO/2001/068609) 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES

Applicants: ACTELION PHARMACEUTICALS LTD. [CH/CH Agent: HOFMANN, Dieter ; StratAll Therwilerstrasse 87 CH Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD.

Actelion Enters Phase III With Novel Orexin Receptor Antagonist

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.

Actelion Annual Report 2006 - Financials - Corporate Governance

Education: Chemist and European Patent Attorney. .As the principal agent for corporate management, the Board of Directors has directed Internal Audit to.

Actelion Annual Report 2006 - Financials - Corporate Governance

1.1.1 Description of Actelion’s operational group structure Chemist and European Patent Attorney. Professional background As the principal agent for corporate management, the Board.

Actelion - Actelion enters Phase III with novel orexin receptor

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.

Actelion Ltd.: New Data On Orexin Receptor Antagonist Almorexant Shows

Of almorexant is compatible with those required for an agent used in sleep disorders. Actelion Almorexant is covered under a recently published patent application. Actelion is now.

Actelion Enters Phase III With Novel Orexin Receptor Antagonist

It was discovered by researchers at Actelion Pharmaceuticals in 2003. Almorexant is covered by a patent application. About RESTORA.